All treatments
Treatment
Xtandi - 40 mg soft capsules clinical trials
2 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic confirmatory (Phase III)
Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostate cancer: ENZARAD
This study is looking at how a new treatment for prostate cancer, called enzalutamide, works when used with standard hormone therapy and radiation. It's for men with prostate cancer that hasn't spread but is considered high-risk. We want to see if this combination stops the cancer from spreading.
For: Localised prostate cancer at high risk of recurrenceAustria · Ireland · Spain - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1/2 Study of EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with Metastatic Castration-Resistant Prostate Cancer
This study is looking at a new drug, EPI-7386, combined with an existing prostate cancer drug, Xtandi. It's for men with advanced prostate cancer that has spread and isn't responding to hormone therapy. Researchers want to see if this combination is safe and if it helps shrink the cancer.
For: Metastatic castration-resistant prostate cancerSpain · Belgium · France